Cartesian Therapeutics, Inc.
RNAC
$6.36
-$0.30-4.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 109.51% | 51.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 109.51% | 51.68% | |||
| Cost of Revenue | 6.43% | -7.18% | |||
| Gross Profit | -2.94% | 8.38% | |||
| SG&A Expenses | 6.23% | 6.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.36% | -2.67% | |||
| Operating Income | -4.14% | 3.42% | |||
| Income Before Tax | -183.46% | -326.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -157.86% | -326.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -157.86% | -326.00% | |||
| EBIT | -4.14% | 3.42% | |||
| EBITDA | -4.26% | 3.59% | |||
| EPS Basic | -157.82% | -370.57% | |||
| Normalized Basic EPS | -5.08% | 2.21% | |||
| EPS Diluted | -158.06% | -376.14% | |||
| Normalized Diluted EPS | -5.08% | 0.46% | |||
| Average Basic Shares Outstanding | 0.01% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.01% | -1.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||